Skip to main content
Heliyon logoLink to Heliyon
. 2020 Jun 27;6(6):e04241. doi: 10.1016/j.heliyon.2020.e04241

1,2,3-Triazole β-lactam conjugates as antimicrobial agents

Rajneesh Kaur a, Raman Singh a, Antresh Kumar b,c, Satvinder Kaur a, Nitesh Priyadarshi d, Nitin Kumar Singhal d, Kuldeep Singh a,
PMCID: PMC7327255  PMID: 32637684

Abstract

A convenient and efficient synthesis of new triazole β-lactam conjugates using click chemistry is described. β-lactam 15 and 16 were prepared using cycloaddition strategy and propargylated at N-1 to afford compounds 17 and 18. Cu-catalyzed click reaction of these β-lactams 17 and 18 with different aryl azides provided 1,2,3-triazole conjugates 6 and 7, respectively. The products were fully characterized spectroscopically and tested against Gram-(+) and Gram-(-) bacteria. Compound 7a and 7c were found to be most active.

Keywords: Pharmaceutical chemistry, Microbiology, Triazole, Beta-lactam, Conjugates, Antibacterial assay


Pharmaceutical chemistry; Microbiology, Triazole; Beta-lactam; Conjugates; Antibacterial assay.

1. Introduction

Preantibiotic era diminished its effect by the discovery of penicillin in 1928 [1]. Different classes of antibiotics such as carbapenem, cephalosporin, monobactams have resulted from the modifications of the azetidin-2-one core [2]. Suitable modifications of key motif azetidin-2-one (monocyclic β-lactams) have displayed many pharmacological activities [3, 4] viz antimalarial [5], anticholesterolemic [6], anti-inflammatory, and antimicrobial [7, 8] activities. As the structural core, monocyclic β-lactam displays a broad spectrum of antimicrobial activity with low toxicity and high efficacy. The main mechanism of the antibacterial action showed an inhibitory effect on essential structural components of bacterial cell wall biosynthesis [9, 10, 11]. Monocyclic β-lactam is the only class of β-lactams that has not become the victim of β-lactamase [12, 13, 14, 15]. Aztreonam and carumonam [16] are two monobactams known for their antimicrobial activity. Aztreonam is the first clinically used synthetic monocyclic β-lactam drug (Figure 1) [17]. 1,2,3-Triazole derivatives have shown promising biological activity, including inhibitory effect against different bacteria [18, 19, 20, 21]. With these inspirations, new 1,2,3-triazole β-lactam conjugates 5 were envisioned.

Figure 1.

Figure 1

Representative examples of monocyclic β-lactam antimicrobials.

In the prevailing literature, the 1,2,3-triazole attached with β-lactam core has been reported to exhibit various pharmaceutical properties [22, 23, 24, 25]. For example, β-lactam core with triazole at C-3 position i.e. 3-(1,2,3-triazol-1-yl)-β-lactams showed anti-plasmodial activity [22]. Ferrocenylchalcone-β-lactam conjugates were active against Plasmodium falciparum [23]. 1,2,3-Triazole tethered β-lactam-chalcone bifunctional hybrids showed anticancer activity [24]. Monocyclic β-lactam with triazole ring at position C-4 i.e. 2-((4-((2-Chloro-5-(trifluoromethyl)benzamido) methyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidin-1-yl 4-methyl benzenesulfonate displayed antimicrobial activity [25]. In our best of knowledge, there is no report on the synthesis of triazole ring at position 1 of the β-lactam ring. i.e., at position N-1. In our present work, generation of triazole ring at the nitrogen of the β-lactam ring is discussed (Figure 2).

Figure 2.

Figure 2

Generation of 1,2,3-triazole on different positions of the β-lactam ring.

The primary mode of action of β-lactams to kill bacteria is inhibition of transpeptidases, which form peptidoglycan by cross-linking the peptides. Absence of cross-linking causes the disruption of the cell wall [11]. Lipophilicity is directly relating the biological activities due to its dependency upon solubility, toxicity, permeability, and protein binding [26]. Lipophilicity plays a vital role in antimicrobial activity due to drug bioavailability (how much molecule permeable to the cell wall). Therefore, a molecule with high lipophilicity would easily penetrate through the cell wall and display the biological effect. Compounds with short alkyl chains are effective against yeast and fungi, whereas bacteria (gram-negative organisms) have susceptible to the compounds with long alkyl chains [27]. Thus, the correlation between activity with lipophilicity can be used to design new molecules or to modify others. Based on these facts, new β-lactams were intended to incorporate long alkyl chains to improve the lipophilicity of the molecule.

The current methodology provides two points to enhance lipophilicity in the scaffolds shown in Figure 3. These molecules could be prepared by generating a triazole linker using Copper(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC) reaction between alkyne 9 and aryl azides 10. The compound 9 could be obtained by propargylation of azetidin-2-one 11 (Scheme 1).

Figure 3.

Figure 3

Synthetic approach to improve lipophilicity.

Scheme 1.

Scheme 1

Synthetic strategy.

2. Results and discussion

Among various reported methods [4, 28, 29, 30] for the preparation of azetidin-2-ones, the cycloaddition of chlorosulphonyl isocyanate (13, CSI) with alkene provides an efficient and one-pot procedure to produce 4-substituted azetidin-2-one derivatives [31]. Under anhydrous and dry reaction conditions, chlorosulphonyl isocyanate 13 undergoes cycloaddition reaction with alkene 14 (n = 1 or 2) to produce azetidin-2-one derivative 15 (n = 1) or 16 (n = 2). Lower yields could be attributed to high reactivity and moisture sensitivity of CSI. Azetidin-2-ones (15 and 16) thus formed were subjected to propargylation using standard propargylation reaction conditions [32, 33] to yield compound 17 and 18 in good yields. These new products were fully characterized spectroscopically. In compound 15 and 16, NH proton appears as a broad singlet at δ 5.85 ppm. The NH broad singlet disappeared in proton NMR of compounds 17 and 18, and characteristics peaks of the acetylenic proton were observed at δ 2.26 (t, 1H, J = 2.56 Hz) ppm. These observations confirm the formation and structure of 17 and 18.

Next, azides 10 were prepared using the literature method from corresponding substituted anilines [34]. These azides were used as ethyl acetate solution without further purification. The ethyl acetate solution of azide can be stored in a refrigerator overnight without loss of reactivity or yield. Having prepared azides and propargyl derivatives 17 and 18, copper-catalyzed Huisgen 1,3-dipolar cycloaddition was tested. Aryl azides 10 were reacted with β-lactam 17 in the presence of Cu(I) catalyst to yield respective cycloadducts 6 in moderate to good yield (Scheme 2). All newly synthesized compounds were fully characterized spectroscopically. In the IR spectrum of the cycloadduct 6a, the absorption bands in the region 1716.68 cm−1 for C=O group, two absorption bands in the region 1519.7, 1338.19 cm−1for NO2 while 1458 cm−1 were observed and the presence of these signals revealed the formation of triazole ring. 1H NMR and 13C NMR spectroscopic data satisfy the structure of these compounds. The triazole ring consists of one proton, which appeared as a singlet at δ 8.13 ppm. The triazole ring is connected with the β-lactam ring by methylene. These protons have appeared as two doublets of doublets at δ 4.71 and 4.45 (J = 15.88 Hz) ppm. Two double doublets at δ 2.63, 3.02 (J = 14.64 Hz), and one multiplet at δ 3.73–3.68 were assigned to protons present in the β-lactam ring. Aromatic protons were appeared as multiplets at δ 8.33–8.30, 8.16–8.14, triplet 8.63 (J = 2.21 Hz) and 7.76 (J = 8.2 Hz) ppm. Protons for the aliphatic chain attached at C-4 of the β-lactam ring showed multiplets at δ 5.82–5.75 ppm and δ 5.02–4.96 ppm for vinylic protons. Other remaining protons of the aliphatic chain appeared as multiplets on δ 2.15–1.51 ppm. 13C NMR spectral data further supported the formation of these cycloadducts. A signal due to the carbonyl carbon of the β-lactam ring appeared at δ 167.14 ppm. Two carbons present in newly formed 1,2,3-triazole ring carbon appeared at δ144.81, 120.55 ppm, while carbon connecting 1,2,3-triazole with β-lactam ring showed the signal at δ 52.02 ppm. These spectroscopic data confirms the formation of the triazole ring and the structure.

Scheme 2.

Scheme 2

Reagents and conditions: (i) DCM, room temperature, (ii) Propargyl bromide, KOH, TBAB, THF (iii) tBuOH:H2O (1:1), Copper acetate, sodium ascorbate.

When different azides 10 were treated with compound 18, the cycloadducts 7 were obtained in moderate to good yield. Mass analysis of 7a (analyzed for C18H21N5O3) showed the molecular ion peak at 356.1717. The IR spectrum displayed vibrations at 1717cm−1 for C=O, 1519, 1338 cm−1 for NO2 while the presence of a signal at 1438 cm−1 revealed the formation of the triazole ring. 1H NMR spectrum of compound 7a showed characteristic spectral features of the β-lactam ring. Two doublets of doublet at δ 2.60, 3.02 (J = 14.64 Hz) ppm, one multiplet appeared around δ 3.70–3.65 ppm were assigned for the protons of the β-lactam ring. The four protons of the aromatic ring appeared as a set of multiplet at δ 7.76, 8.18, 8.33, and 8.63 ppm. The singlet at δ 8.16 ppm was assigned to proton present at C-5 carbon of 1,2,3-triazole ring. Two doublets at δ 4.43 ppm and 4.71 ppm were due to methylene protons connecting the β-lactam ring with a triazole ring. 13C NMR spectrum showed 18 signals. The signal due to the carbonyl carbon of the β-lactam ring appeared at δ 167.27 ppm. Two carbons of the 1,2,3-triazole ring appeared at δ 144.8, and 120.5 ppm. The carbon linking 1,2,3-triazole with β-lactam ring showed a signal at δ 52.3 ppm. The signals due to carbons in the aliphatic chain appeared in the region δ 42.6–24.8 ppm, while that of CH2 = CH appeared at 115.3 and 114.7 ppm. Remaining signals in the region between δ148.97–115.3 ppm were attributed to carbons in the aromatic ring attached to the triazole ring. All spectroscopic data confirm the structure of cycloadduct 7a. The physical properties of synthesized compounds are summarized in Table 1.

Table 1.

Physical properties of compound 6 and 7.

Compound R Color Physical State MP (°C)
6a 3-NO2 White Solid 35–37
6b 4-NO2 White Semi-solid -
6c 3-Cl White Semi-solid -
6d 4-Cl White Semi-solid -
6e 4-OMe White Semi-solid -
6f Benzyl White Semi-solid -
7a 3-NO2 Pale yellow Semi-solid -
7b 4-NO2 White Semi-solid -
7c 3-Cl White Solid 228–230
7d 4-Cl White Semi-solid -
7e 4-OMe White Semi-solid -

2.1. Antimicrobial activity and structure activity relationship

All compounds were screened by spot assay method against Pseudomonas aeruginosa MTCC1034, Bacillus subtilis MTCC441 and methicillin-sensitive S. aureus (MSSA) ATCC29213 (Table 2). All compounds were inactive against S. aureus. Among the synthesized compounds, having electron-withdrawing groups (nitro, chloro) at 3rd-position of benzene ring were found to be active for P. aeruginosa, and B. subtilis. Compounds with electron-withdrawing group NO2 and electron releasing OCH3 at p-position was inactive against P. aeruginosa but showed moderate activity against B. subtilis. p-Cl substituted compounds showed moderate activity against P. aeruginosa, B. subtilis. Overall, substitution at meta-position was found useful. Compounds with a long alkyl chain displayed better activity. Compound 7a found most active among the series. To conclude it, Compound 7a could be carried forward to further studies.

Table 2.

Antimicrobial activity of synthesized compounds.

Compound MIC(μg/ml)
B. subtilis
MIC(μg/ml)
P. aeruginosa
6a 5 10
6b 20 40
6c 10 5
6d ND ND
6e 5 10
6f 20 5
7a 1.25 1.25
7b ND ND
7c 1.25 1.25
7d ND ND
7e 20 10
Standard drug (ampicillin) 0.5 1

3. Conclusion

In conclusion, a methodology to prepare triazole-2-azetidinone conjugates is described. In this methodology, the triazole ring was installed at the N-1 of the azetidin-2-one ring using a methylene tether. These final products were fully characterized spectroscopically and tested against Gram-(+) and Gram-(-) bacteria. Compound 7a and 7c were found to be most active. Further, compounds 7 are more lipophilic and is more active as compared to compounds 6, due to the presence of a long side chain.

4. Experimental

All chemicals and solvents were purchased from Merck, Spectrochem, and/or S. D. Fine-chem. Melting points were determined by open capillary using the digital melting point apparatus and are uncorrected. 1H NMR, and 13C NMR spectra were recorded in deuteron chloroform with Bruker Advance II spectrometer (400 and 100 MHz, 500 and 126 MHz, respectively) in CDCl3 or DMSO-d6 using TMS as an internal standard. The chemical shift values are expressed as parts per million downfield from TMS, and J values are in hertz. Splitting patterns are indicated as s: singlet, d: doublet, t: triplet, m: multiplet, dd: double doublet, and br: broad peak. High-resolution mass spectra were recorded on Bruker-micrOTOF-Q II spectrometer. Column chromatography was performed on a silica gel (100–200 mesh). Thin-layer chromatography was used to monitor the progress of the reactions. Spectral data and copies of spectra are available as supplementary content online.

4.1. General procedure for preparation of N-propargylated azetidin-2-one (17 and 18) [31]

Handling of chlorosulphonyl isocyanate [35]: Chlorosulphonyl isocyanate is the most chemically reactive isocyanate known and reacts violently with water (Danger!). It can be stored indefinitely in sealed glass ampules, but polyethylene bottles with screw caps are best suited for storage in the laboratory at 4 °C. It should be used in a well ventilated and efficient fumehood. Reaction systems and equipment must be scrupulously dry. Appropriate eye protection, protective gloves, and protective clothing should be used. In case of fire, DO NOT USE WATER! Use dry chemical, dry sand, or carbon dioxide extinguishing media.

Azetidin-2-one (15 or 16) was synthesized by reacting chlorosulphonyl isocyanate (0.01 mol) with 1,5-hexadiene or 1,7-octadiene (0.01 mol) using modified literature method [31]. Prepared Azetidin-2-one (2.94 mmol, 1 equiv.) reacted with propargyl bromide (3.23 mmol 1.1 equiv.) in the presence of KOH (3.23 mmol, 1.1 equiv.) and tertiary butyl ammonium bromide (0.47mmol, 0.16 equiv.) in anhydrous THF (5 mL) stirred under nitrogen at room temperature for 3h monitored by TLC. Then, the mixture extracted with ethyl acetate, washed with water to afford the corresponding 4-(but-3-en-1-yl)-1-(prop-2-yn-1-yl)azetidin-2-one 17 or 4-(hex-5-en-1-yl)azetidin-2-one 18 respectively. Purification with column chromatography (Silica gel, 100–200 mesh; pet ether: ethyl acetate) afforded pure products.

4.2. General procedure for click reaction [36, 37]

To a solution of N-propargyated azetidin-2-one (17 or 18), substituted azide 10, cupric acetate (10 mol%), and sodium ascorbate (20% mol) were added in a solution of water (4 mL) and tert-butyl alcohol (4 mL) at room temperature with stirring for 24 h. Upon completion of the reaction (monitored by TLC), the mixture was diluted with water, extracted with ethyl acetate, and dried over anhydrous Na2SO4. After evaporation of the solvent, the final compounds were chromatographed (DCM/Methanol) to yield pure products (6 or 7).

4-(but-3-en-1-yl)-1-((4-(3-nitrophenyl)-1H-1,2,3-triazol-1-yl)methyl)azetidin-2-one (6a) White color, MP:35–37 °C, Yield: 877 mg, 80%, FTIR (thin film, cm−1) 1716.68, 1519.7, 1412.96, 1338.19; 1H (400 MHz, CDCl3, ppm): 8.63 (t, 1H, J = 2.08 Hz), 8.33–8.30 (m, 1H), 8.16–8.14 (m, 1H), 8.13 (s, 1H), 7.76 (t, 1H, J = 8.2 Hz), 5.84–5.74 (m, 1H), 5.06–4.98 (m, 2H), 4.71 (d, 1H, J = 15.84 Hz), 4.45 (d, 1H, J = 15.88 Hz) 3.73–3.68 (m, 1H), 3.03 (dd, 1H, J = 4.92, 14.68 Hz), 2.63 (dd, 1H, J = 2.28, 14.64 Hz), 2.15–2.02 (m, 3H), 1.58–1.51 (m, 1H);13C (100 MHz, CDCl3, ppm) 167.14, 148.97, 144.81, 137.62, 137.01, 131.02, 125.82, 123.35, 120.55, 115.66, 115.36, 52.02, 42.70, 35.87, 32.05, 29.72; HRMS (ESI): m/z calcd for C16H18N5O3 (M + H): 328.1410; found 328.1404.

4-(but-3-en-1-yl)-1-((4-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)methyl)azetidin-2-one (6b) White color, semi solid, Yield: 789 mg, 72%; FTIR (thin film, cm−1) 1717.74, 1519.79, 1438.91, 1412.96, 1339.88; 1H NMR (400 MHz, CDCl3, ppm): 8.45–8.40 (m, 2H), 8.13 (s, 1H), 8.00–7.96 (m, 2H), 5.82–5.73 (m, 1H), 5.06–4.98 (m, 2H), 4.70 (d, 1H, J = 15.88 Hz), 4.45 (d, 1H, J = 15.88 Hz), 3.72–3.69 (m, 1H), 3.02 (dd, 1H, J = 4.96, 14.68 Hz), 2.62 (dd, 1H, J = 2.32, 14.68 Hz), 2.15–2.04 (m, 3H), 1.53–1.59 (m, 1H); 13C (100 MHz, CDCl3, ppm) 167.15, 147.33, 144.93, 141.00, 136.94, 125.60, 120.53, 120.49, 115.68, 52.04, 42.72, 35.84, 32.04, 29.74; HRMS (ESI): m/z calcd for C16H18N5O3 (M + H): 328.1410; found 328.1407.

4-(but-3-en-1-yl)-1-((4-(3-chlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)azetidin-2-one (6c) White color, semi solid, Yield: 210 mg, 72%; FTIR (thin film, cm−1): 1663, 1406.56, 1436.31, 1310.89, 1260.86, 1026.51, 953.13, 800.44, 698.83, 668.64, 532.80; 1H (400 MHz, CDCl3, ppm): 8.03 (s, 1H), 7.79 (t, 1H, J = 1.92 Hz), 7.64–7.62 (m, 1H), 7.48–7.40 (m, 2H), 5.81–5.72 (m, 1H), 5.05–5.00 (m, 2H), 4.69 (d, 1H, J = 15.8 Hz), 4.42 (d, 1H, J = 15.8 Hz), 3.71–3.67 (m, 1H), 3.01 (dd, 1H, J = 4.92, 14.64 Hz), 2.61 (dd, 1H, J = 2.2, 14.64 Hz), 2.13–2.00 (m, 3H) 1.57–1.51 (m, 1H); 13C (100 MHz, CDCl3, ppm) 167.28, 144.17, 139.27, 137.74, 137.04, 135.68, 130.89, 128.98, 120.60, 115.61, 114.08, 52.00, 42.58, 35.89, 33.82, 28.97; HRMS (ESI): m/z calcd for C16H18ClN4O (M + H): 317.1169; found 317.1164.

4-(but-3-en-1-yl)-1-((4-(4-chlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)azetidin-2-one (6d) White color, semi solid, Yield: 317 mg, 82%; FTIR (thin film, cm−1): 1660, 1436.3, 1405.5,1310.8, 1260.8, 1026.5, 953.1, 1H (400 MHz, CDCl3, ppm): 7.99 (s, 1H), 7.70–7.67 (m, 2H), 7.53–7.49 (m, 2H), 5.81–5.72 (m, 1H), 5.05–4.97 (m, 2H), 4.69 (d, 1H, J = 15.8 Hz), 4.42 (d, 1H, J = 15.8 Hz), 3.70–3.66 (m, 1H), 3.01 (dd, 1H, J = 4.96, 14.64 Hz), 2.61 (dd, 1H, J = 2.28, 14.64 Hz), 2.13–2.02 (m, 3H), 1.57–1.52 (m, 1H); 13C (100 MHz, CDCl3, ppm): 167.09, 144.16, 137.05, 135.36, 134.69, 129.98,121.62, 120.50, 115.58, 51.89, 42.60, 35.83, 31.97, 29.69; HRMS (ESI): m/z calcd for C16H18ClN4O (M + H): 317.1169; found 317.1188.

4-(but-3-en-1-yl)-1-((4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)methyl)azetidin-2-one (6e) White color, semi solid, Yield: 468 mg, 64%; FTIR (thin film, cm−1): 1667, 1559, 1520, 1497, 1243, 1194, 1158, 1029, 927; 1H (400 MHz, CDCl3, ppm): 7.90 (s, 1H), 7.63–7.60 (m, 2H), 7.04–7.00 (m, 2H), 5.82–5.72 (m, 1H), 5.05–4.96 (m, 2H), 4.69 (d, 1H, J = 15.72 Hz), 4.40 (d, 1H, J = 15.76 Hz), 3.87 (s, 3H), 3.70–3.65 (m, 1H), 3.00 (dd, 1H, J = 4.96, 14.6 Hz), 2.60 (dd, 1H, J = 2.36, 14.6 Hz), 2.13–2.00 (m, 3H)1.57–1.49 (m, 1H); 13C (100 MHz, CDCl3, ppm) 167.04,159.94, 143.67, 137.11, 130.38, 122.13, 120.65, 115.54, 114.82, 55.64, 51.81, 42.57, 35.88, 31.97, 29.70; HRMS (ESI): m/z calcd for C17H20N4NaO2 (M + Na): 335.1484; found 335.1478.

1-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-4-(but-3-en-1-yl)azetidin-2-one (6f) White color, semi solid, Yield: 442 mg, 61%; FTIR (thin film, cm−1): 1660.19, 1406.8, 1436.43, 1310.92, 1027.92, 953.4, 699.10, 668.83, 560.46; 1H (400 MHz, CDCl3, ppm): 7.44 (s, 1H), 7.39–7.35 (m, 3H), 7.28–7.24 (m, 2H), 5.78–5.68 (m, 1H), 5.50 (m, 2H), 5.01–4.94 (m, 2H), 4.57 (d, 1H, J = 15.72 Hz), 4.32 (d, 1H, J =15.72 Hz), 3.63–3.58 (m, 1H), 2.95 (dd, 1H, J = 4.96, 14.96 Hz), 2.54 (dd, 1H, J = 2.32, 14.56 Hz), 2.07–2.02 (m, 2H), 1.99–1.92 (m, 1H), 1.50–1.42 (m, 1H). 13C (100 MHz, CDCl3, ppm): 166.91, 143.57, 137.11, 134.41, 129.17, 128.86, 128.08, 122.15, 115.44, 54.28, 51.75, 42.48, 35.89, 31.93, 31.63, 29.63; HRMS (ESI): m/z calcd for C17H20N4NaO (M + Na): 319.1535; found 319.1538.

4-(hex-5-en-1-yl)-1-((1-(3-nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)azetidin-2-one (7a) pale yellow color, semi solid, Yield: 451 mg, 75%; FTIR (thin film, cm−1): 1717, 1436, 1406, 1313,1018, 952, 889, 669; 1H (400 MHz, CDCl3, ppm): 8.63 (t, 1H, J = 2.08 Hz), 8.33–8.30 (m, 1H), 8.17–8.15 (m, 1H), 8.16 (s, 1H), 7.76 (t, 1H, J = 8.2 Hz), 5.82–5.72 (m, 1H), 5.02–4.92 (m, 2H), 4.71 (d, 1H, J = 15.88 Hz), 4.43(d 1H, J = 15.84 Hz), 3.70–3.65 (m, 1H), 3.02 (dd, 1H, J = 4.92, 14.6 Hz), 2.60 (dd, 1H, J = 2.28, 14.64 Hz), 2.07–1.97 (m, 2H), 1.95–1.90 (m, 1H), 1.51–1.30 (m, 5H); 13C (100 MHz, CDCl3, ppm): 167.27, 148.96, 144.81, 138.41, 137.6, 131.04, 125.82, 123.34, 120.57, 115.33, 114.78, 52.33, 42.63, 35.82, 33.53, 32.66, 28.64, 24.83; HRMS (ESI): m/z calcd for C18H22N5O3 (M + H): 356.1723; found 356.1717.

4-(hex-5-en-1-yl)-1-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)azetidin-2-one (7b) White color, semi solid, Yield: 505 mg, 84%; FTIR (thin film, cm−1): 1716.7, 1519, 1504,1338, 1232, 1040, 852, 749; 1H (400 MHz, CDCl3, ppm): 8.44–8.40 (m, 2H), 8.13(s. 1H), 7.99–7.95 (m, 2H), 5.80–5.71 (m, 1H), 5.01–4.93 (m, 2H), 4.69 (d, 1H, J = 15.84 Hz), 4.42 (d, 1H, J = 15.84 Hz), 3.68–3.64 (m, 1H), 3.01 (dd, 1H, J = 4.96, 14.64 Hz), 2.59 (dd, 1H, J = 2.24, 14.6 Hz), 2.07–2.02 (m, 2H), 1.95–1.91 (m, 1H), 1.48–1.25 (m, 5H); 13C (100 MHz, CDCl3, ppm): 167.28, 147.32, 144.98, 140.98, 138.52, 125.61, 120.22, 120.48, 114.8, 52.38, 42.65, 35.81, 33.53, 32.68, 28.64, 24.82; HRMS (ESI): m/z calcd for C18H22N5O3 (M + H): 356.1723; found 356.1728.

1-((1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-(hex-5-en-1-yl)azetidin-2-one (7c) White color, MP: 228–230 °C, Yield: 134 mg, 71%; FTIR (thin film, cm−1): 1661, 1407, 1439, 1311, 1268, 1015, 954; 1H (500 MHz, CDCl3, ppm): 7.80 (t, 1H, J = 1.92 Hz), 7.65–7.63 (m, 1H), 7.49–7.41 (m, 2H), 8.15 (s, 1H), 5.83–5.75 (m, 1H), 5.01–4.92 (m, 2H), 4.68 (d, 1H, J = 15.8 Hz), 4.43 (d, 1H, J = 15.8 Hz), 3.69–3.63 (m, 1H), 3.01 (dd, 1H, J = 4.92, 14.64 Hz), 2.60 (dd, 1H, J = 2.2, 14.64 Hz), 2.09–2.00 (m, 2H), 1.99–1.93 (m, 2H), 1.49–1.41 (m, 1H), 1.40–1.36 (m, 1H), 1.34–1.24 (m, 2H); 13C (126 MHz, CDCl3, ppm): 167.08, 144.15, 139.05, 137.67, 136.98, 135.27, 130.87, 128.92, 120.52, 115.34, 114.05, 51.81, 42.37, 35.73, 33.42, 32.41, 29.45, 24.81; HRMS (ESI): m/z calcd for C18H22ClN4O (M + H): 345.1482; found 345.1450.

1-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-(hex-5-en-1-yl)azetidin-2-one (7d) White color, semi solid, Yield: 261 mg, 67%; FTIR (thin film, cm−1): 1735, 1502, 1403, 1239, 1093, 1049, 987, 842; 1H (500 MHz, DMSO, ppm): 8.80 (s, 1H), 7.95 (d, 2H, J = 8.5 Hz), 7.65 (d, 2H, J = 8.5 Hz), 5.75–5.70 (m, 1H), 4.96–4.88 (m, 2H), 4.60 (d, 1H, J = 16 Hz), 4.34 (d, 1H, J = 15.5 Hz), 3.59 (d, 1H, J = 4 Hz), 2.95 (dd, 1H, J = 5, 14.5 Hz), 2.52 (d, 1H, J= 17 Hz), 1.98–1.94 (m, 2H), 1.81–1.76 (m, 1H), 1.41–1.35 (m, 1H), 1.33–1.26 (m, 2H), 1.25–1.20 (m, 2H); 13C (126 MHz, DMSO, ppm): 166.54, 144.3, 138.98, 135.86, 133.37, 130.28, 122.06, 121.9, 115.16, 51.63, 42.38, 35.72, 33.47, 32.38, 28.57, 24.73; HRMS (ESI): m/z calcd for C18H22ClN4O (M + H): 345.1482; found 345.1456.

4-(hex-5-en-1-yl)-1-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)azetidin-2-one (7e) White color, semi solid, Yield: 163 mg, 61%; FTIR (thin film, cm−1): 1662,1554, 1518, 1496, 1248, 1197, 1160, 1031, 931; 1H NMR (500 MHz, DMSO, ppm): 8.65 (s, 1H), 7.80 (d, 2H, J = 9 Hz), 7.14 (d, 2H, J = 8.5 Hz), 5.79–5.72 (m, 1H), 4.98–4.90 (m, 2H), 4.58 (d, 1H, J = 16 Hz), 4.32 (d, 1H, J = 15.5 Hz), 3.83 (s, 3H), 3.59–3.37 (m, 1H), 2.96 (dd, 1H, J = 5, 14.6 Hz), 2.59 (dd, 1H, J = 2.28, 14.6 Hz), 2.01–1.96 (m, 2H), 1.83–1.78 (m, 1H), 1.43–1.30 (m, 3H), 1.27–1.22 (m, 2H); 13C NMR (126 MHz, CDCl3, ppm): 166.55, 159.73, 143.83, 139.04, 130.29, 122.11, 121.81, 115.35, 115.24, 56.05, 51.6, 42.34, 35.74, 33.47, 32.37, 28.57, 24.63; HRMS (ESI): m/z calcd for C19H24N4NaO2 (M + Na): 363.1797; found 363.1791.

Declarations

Author contribution statement

Kuldeep Singh, Raman Singh: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.

Rajneesh Kaur: Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Antresh Kumar: Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Nitin Kumar Singhal, Nitesh Priyadarshi, Satvinder Kaur: Contributed reagents, materials, analysis tools or data; Wrote the paper.

Funding statement

Kuldeep Singh was supported by the Science and Engineering Research Board (CS-017/2014).

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

Acknowledgements

R.K. thanks SERB New Delhi for a Fellowship. We wish to thank the SAIF Panjab University, Chandigarh, for help in spectroscopic measurements. The authors are thankful to MMDU for infrastructure support.

Appendix A. Supplementary data

The following is the supplementary data related to this article:

Supplementary content

mmc1.pdf (2.7MB, pdf)

References

  • 1.Durand G.A., Raoult D., Dubourg G. Antibiotic discovery: history, methods and perspectives. Int. J. Antimicrob. Agents. 2019 doi: 10.1016/j.ijantimicag.2018.11.010. [DOI] [PubMed] [Google Scholar]
  • 2.Myers B. Early discoveries in the penicillin series. React. Biochem. 1991:195–197. doi: 10.1016/0968-0004(91)90076-8. [DOI] [PubMed] [Google Scholar]
  • 3.Kaur R., Singh R., Ahlawat P., Kaushik P., Singh K. Contemporary advances in therapeutic portfolio of 2-azetidinones. Chem. Biol. Lett. 2020;7:13–26. [Google Scholar]
  • 4.Kaur R., Tripathi D., Singh K., Singh R. Recent advances in β-lactam chemistry. Integr. Res. Adv. 2018;5:52–57. [Google Scholar]
  • 5.Rad J.A., Jarrahpour A., Latour C., Sinou V., Brunel J.M., Zgou H., Mabkhot Y., Ben Hadda T., Turos E. Synthesis and antimicrobial/antimalarial activities of novel naphthalimido trans-β-lactam derivatives. Med. Chem. Res. 2017;26:2235–2242. [Google Scholar]
  • 6.Yuan X., Lu P., Xue X., Qin H., Fan C., Wang Y., Zhang Q. Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors. Bioorg. Med. Chem. Lett. 2016;26:849–853. doi: 10.1016/j.bmcl.2015.12.077. [DOI] [PubMed] [Google Scholar]
  • 7.Arya N., Jagdale A.Y., Patil T.A., Yeramwar S.S., Holikatti S.S., Dwivedi J., Shishoo C.J., Jain K.S. The chemistry and biological potential of azetidin-2-ones. Eur. J. Med. Chem. 2014;74:619–656. doi: 10.1016/j.ejmech.2014.01.002. [DOI] [PubMed] [Google Scholar]
  • 8.Agarwal S., Garg D.K., Agarwal A. Synthesis, characterization and evaluation of antimicrobial activity of novel hybrid moieties-benzothiazoles and azetidinones. Chem. Biol. Interface. 2016;6:99–108. [Google Scholar]
  • 9.Page M.I. Springer Netherlands; 2012. The Chemistry of β-Lactams. [Google Scholar]
  • 10.Tomasz A. The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria. Annu. Rev. Microbiol. 1979;33:113–137. doi: 10.1146/annurev.mi.33.100179.000553. [DOI] [PubMed] [Google Scholar]
  • 11.Smith P.W., Zuccotto F., Bates R.H., Santos M., Read K.D., Peet C., Epemolu O., Smith P.W., Zuccotto F., Bates R.H., Martinez-martinez M.S., Read K.D., Peet C., Epemolu O. 2018. Perspective : Pharmacokinetics of Beta Lactam Antibiotics : Clues from the Past to Help Discover Long Acting Oral Drugs in the Future Perspective : Pharmacokinetics of Beta Lactam Antibiotics : Clues from the Past to Help Discover Long Acting Oral Drugs I. [Google Scholar]
  • 12.Rang H.P., Dale M.M., Ritter J.M., Moore P.K. fifth ed. Churchill Livingstone; 2003. Pharmacology. [Google Scholar]
  • 13.Decuyper L., Jukič M., Sosič I., Žula A., D’hooghe M., Gobec S. Antibacterial and β-lactamase inhibitory activity of monocyclic β-lactams. Med. Res. Rev. 2018;38:426–503. doi: 10.1002/med.21443. [DOI] [PubMed] [Google Scholar]
  • 14.Fernandes R., Amador P., Prudêncio C. β-Lactams. Rev. Med. Microbiol. 2013;24:7–17. [Google Scholar]
  • 15.Bush K., Bradford P.A. Interplay between β-lactamases and new β-lactamase inhibitors. Nat. Rev. Microbiol. 2019;17:295–306. doi: 10.1038/s41579-019-0159-8. [DOI] [PubMed] [Google Scholar]
  • 16.Imada A., Kondo M., Okonogi K., Yukishige K., Kuno M. In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic β-lactam antibiotic. Antimicrob. Agents Chemother. 1985;27:821–827. doi: 10.1128/aac.27.5.821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Neu H.C. Aztreonam: the first monobactam. Med. Clin. North Am. 1988;72:555–566. doi: 10.1016/s0025-7125(16)30758-1. [DOI] [PubMed] [Google Scholar]
  • 18.López-Rojas P., Janeczko M., Kubiński K., Amesty Á., Masłyk M., Estévez-Braun A. Synthesis and antimicrobial activity of 4-substituted 1,2,3-triazole-coumarin derivatives. Molecules. 2018;23:199. doi: 10.3390/molecules23010199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Petrova K.T., Potewar T.M., Correia-da-Silva P., Barros M.T., Calhelha R.C., Ćiric A., Soković M., Ferreira I.C.F.R. Antimicrobial and cytotoxic activities of 1,2,3-triazole-sucrose derivatives. Carbohydr. Res. 2015;417:66–71. doi: 10.1016/j.carres.2015.09.003. [DOI] [PubMed] [Google Scholar]
  • 20.Dheer D., Singh V., Shankar R. Medicinal attributes of 1,2,3-triazoles: current developments. Bioorg. Chem. 2017;71:30–54. doi: 10.1016/j.bioorg.2017.01.010. [DOI] [PubMed] [Google Scholar]
  • 21.Sumangala V., Poojary B., Chidananda N., Fernandes J., Kumari N.S. Synthesis and antimicrobial activity of 1,2,3-triazoles containing quinoline moiety. Arch. Pharm. Res. 2010;33:1911–1918. doi: 10.1007/s12272-010-1204-3. [DOI] [PubMed] [Google Scholar]
  • 22.Singh P., Sachdeva S., Raj R., Kumar V., Mahajan M.P., Nasser S., Vivas L., Gut J., Rosenthal P.J., Feng T.S., Chibale K. Antiplasmodial and cytotoxicity evaluation of 3-functionalized 2-azetidinone derivatives. Bioorg. Med. Chem. Lett. 2011;21:4561–4563. doi: 10.1016/j.bmcl.2011.05.119. [DOI] [PubMed] [Google Scholar]
  • 23.Kumar K., Pradines B., Madamet M., Amalvict R., Kumar V. 1H-1,2,3-triazole tethered mono- and bis-ferrocenylchalcone-β-lactam conjugates: synthesis and antimalarial evaluation. Eur. J. Med. Chem. 2014;86:113–121. doi: 10.1016/j.ejmech.2014.08.053. [DOI] [PubMed] [Google Scholar]
  • 24.Singh P., Raj R., Kumar V., Mahajan M.P., Bedi P.M.S., Kaur T., Saxena A.K. 1,2,3-Triazole tethered β-lactam-Chalcone bifunctional hybrids: synthesis and anticancer evaluation. Eur. J. Med. Chem. 2012;47:594–600. doi: 10.1016/j.ejmech.2011.10.033. [DOI] [PubMed] [Google Scholar]
  • 25.Carosso S., Miller M.J., Carosso S., Miller M.J. Syntheses and studies of new forms of N -sulfonyloxy β -lactams as potential antibacterial agents and β -lactamase inhibitors. Bioorg. Med. Chem. 2015 doi: 10.1016/j.bmc.2015.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hann M.M. Molecular obesity, potency and other addictions in drug discovery, Multifaceted Roles Crystallogr. Mod. Drug Discov. 2015;2:183–196. [Google Scholar]
  • 27.El Hage S., Lajoie B., Stigliani J.L., Furiga-Chusseau A., Roques C., Baziard G. Synthesis, antimicrobial activity and physico-chemical properties of some n-alkyldimethylbenzylammonium halides. J. Appl. Biomed. 2014;12:245–253. [Google Scholar]
  • 28.Deketelaere S., Van Nguyen T., Stevens C.V., D’hooghe M. Synthetic approaches toward monocyclic 3-Amino-β-lactams. Chem. Open. 2017;6:301–319. doi: 10.1002/open.201700051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ombito J.O., Singh G.S. Recent progress in chemistry of β-lactams. Mini-Reviews Org. Chem. 2019;16:544–567. [Google Scholar]
  • 30.Pitts C.R., Lectka T. Chemical synthesis of β-lactams: asymmetric catalysis and other recent advances. Chem. Rev. 2014;114:7930–7953. doi: 10.1021/cr4005549. [DOI] [PubMed] [Google Scholar]
  • 31.Bateson J.H., Baxter A.J.G., Roberts P.M., Smale T.C., South-gate R. Olivanic acid analogues. Part I. Total synthesis of the 7-0xo-l- azabicyclo[3.2.0] hept-2-ene-2-carboxylate system and some related β-lactams. J. Chem. Soc. Perkin Trans. 1981;1:3242–3249. [Google Scholar]
  • 32.Kotha S., Singh K. N-Alkylation of diethyl acetamidomalonate: synthesis of constrained amino acid derivatives by ring-closing metathesis. Tetrahedron Lett. 2004;45:9607–9610. [Google Scholar]
  • 33.Kotha S., Singh K. Cross-enyne and ring-closing metathesis cascade: a building-block Approach suitable for diversity-oriented synthesis of densely functionalized macroheterocycles with amino acid scaffolds. Eur. J. Org Chem. 2007;2007:5909–5916. [Google Scholar]
  • 34.Kotha S., Goyal D., Bansal) née, Banerjee S., Datta A. A novel di-triazole based peptide as a highly sensitive and selective fluorescent chemosensor for Zn2+ ions. Analyst. 2012;137:2871. doi: 10.1039/c2an35222b. [DOI] [PubMed] [Google Scholar]
  • 35.Bellettini J.R., Miller M.J. A short synthesis of an important precursor to a new class of bicyclic β-lactamase inhibitors. Tetrahedron Lett. 1997;38:167–168. [Google Scholar]
  • 36.Kaur R., Singh R., Kumar A., Singh K. Click chemistry approach to isoindole-1,3-dione tethered 1,2,3-triazole derivatives. SynOpen. 2019;3:67–70. [Google Scholar]
  • 37.Haldón E., Nicasio M.C., Pérez P.J. Copper-catalysed azide–alkyne cycloadditions (CuAAC): an update. Org. Biomol. Chem. 2015;13:9528–9550. doi: 10.1039/c5ob01457c. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary content

mmc1.pdf (2.7MB, pdf)

Articles from Heliyon are provided here courtesy of Elsevier

RESOURCES